Table 2.
Characteristic | Schedule A* (N = 32) | Schedule B† (N = 36) |
---|---|---|
Age (y) | ||
Mean (SD) | 61.2 (9.62) | 62.3 (13.25) |
Median | 61.0 | 61.0 |
Minimum, maximum | 45, 82 | 38, 79 |
Sex | ||
Male | 20 (63%) | 22 (61%) |
Female | 12 (38%) | 14 (39%) |
Ethnicity | ||
Hispanic or Latino | 0 | 1 (3%) |
Not Hispanic or Latino | 31 (97%) | 34 (94%) |
Unknown | 1 (3%) | 1 (3%) |
Race | ||
White | 27 (84%) | 29 (80%) |
Black | 5 (16%) | 6 (17%) |
Other | 0 | 1 (3%) |
SD, standard deviation.
Schedule A dosing was once weekly on days 1, 8, and 15 of 4-week cycles.
Schedule B dosing was twice weekly on days 1, 4, 8, and 11 of 3-week cycles; schedule B patients could receive low-dose Dex.